5/5/2022 4:17:23 PM
Nektar Therapeutics Q1 Loss/share $0.49 Vs. Loss $0.68 Year Ago
4/14/2022 5:05:28 PM
Nektar, Bristol Myers Announce Update On Clinical Development Program For Bempegaldesleukin In Combination With Opdivo
2/28/2022 4:21:19 PM
Nektar Therapeutics Q4 Loss/share $0.79 Vs. Loss $0.65 Year Ago
12/13/2021 9:05:23 AM
Nektar Therapeutics Presents Data For NKTR-255 In Patients With Relapsed/Refractory Hematologic Malignancies
11/30/2021 8:05:29 AM
Nektar Therapeutics Announces Data Presentations For Its Immuno-Oncology Programs
11/15/2021 8:32:53 AM
Nektar Therapeutics Appoints Diana Brainard As Independent Director To Board
11/12/2021 7:02:52 AM
Nektar Announces Data Presentations For Its Immuno-Oncology Pipeline At The 2021 Society For Immunotherapy Of Cancer
11/4/2021 4:27:53 PM
Nektar Therapeutics Q3 Loss/share $0.70 Vs. Loss $0.61 Year Ago
9/21/2021 9:08:08 AM
Nektar Collaborates With Merck KGaA And Pfizer To Combine NKTR-255 With Avelumab In JAVELIN Bladder Medley Study
8/5/2021 4:16:50 PM
Nektar Therapeutics Q2 Loss/share $0.69 Vs. Loss $0.45 Year Ago